Aditxt, INC 8-K filings

Aditxt, Inc. hosted a virtual fireside chat to update stakeholders on key corporate developments, including the planned IPO of its subsidiary, Pearsanta, and progress in other business areas.

Aditxt's board has authorized management to explore an initial public offering for its subsidiary, Pearsanta, focused on early cancer detection.

Aditxt's subsidiary, Adimune, has successfully completed preclinical efficacy and safety studies for its ADI-100 immune modulation therapy, paving the way for first-in-human clinical trials.

Aditxt Inc. has filed an amendment to its merger report, including Evofem's financials for the nine months ended September 30, 2024, and pro forma consolidated financial information.

Aditxt, Inc. has further amended its agreement to acquire Appili Therapeutics, extending the outside date for the transaction to November 19, 2024, and providing updated financial statements.

Aditxt, Inc. and Evofem Biosciences, Inc. have agreed to extend the deadline for their merger to January 31, 2025.

Aditxt held a stakeholder update to discuss NASDAQ compliance, acquisition financing, and strategic business plans, emphasizing a focus on minimizing dilution and building long-term value.

Aditxt, Inc. has entered into a securities purchase agreement to acquire Evofem Biosciences, marking a significant step in expanding its focus on women's health.

Aditxt, Inc. has appointed Sylvia Hermina to its Board of Directors, bringing over 20 years of experience in corporate governance, mergers and acquisitions, and shareholder relations.

Aditxt's CEO, Amro Albanna, addressed stakeholder concerns regarding NASDAQ compliance, capital structure, and the company's strategic direction in a recent update.

Aditxt, Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing, triggering a potential delisting process.

Evofem Biosciences has entered into a securities purchase agreement with Aditxt, Inc., resulting in a $460,000 investment through the issuance of Series F-1 Convertible Preferred Stock.

Aditxt, Inc. has entered into a series of agreements including a senior note issuance for $600,000, a preferred stock purchase, and a market development collaboration with Evofem Biosciences.

Aditxt, Inc. presented its business model focused on acquiring and accelerating innovative healthcare companies at the H.C. Wainwright 26th Annual Global Investment Conference.

Aditxt and Evofem have amended their merger agreement for the second time, adjusting the timing and amounts of planned equity investments and extending the merger closing deadline.

Aditxt, Inc. files an amendment to its previous 8-K report, including historical financial statements for Evofem Biosciences and pro forma financial information related to the merger.

Aditxt, Inc. has further amended its agreement to acquire Appili Therapeutics, extending the outside date for the transaction to November 19, 2024, and adjusting other key deadlines.

Aditxt, Inc. has extended the maturity date of its May Senior Notes to September 30, 2024, and agreed to allocate a portion of future capital raises to repay these notes and redeem preferred stock.

Aditxt, Inc. and Appili Therapeutics, Inc. have agreed to a third amendment to their acquisition agreement, further extending the outside date for the deal to November 19, 2024, and adjusting other key deadlines.

Aditxt, Inc. has finalized a merger agreement with Evofem Biosciences, Inc., completing a $500,000 investment and setting the stage for Evofem to become a wholly-owned subsidiary.

Aditxt, Inc. has successfully completed a registered direct offering, raising approximately $1.2 million to support its merger agreement and general corporate needs.

Aditxt Inc. has increased its authorized common stock to 1 billion shares and gained approval for a potential reverse stock split at its 2024 annual meeting.

Aditxt, Inc. has entered into a securities exchange agreement, issuing preferred stock and warrants in exchange for previously held warrants.

Aditxt, Inc. has amended its merger agreement with Evofem Biosciences, Inc., and included historical financial statements and pro forma information.

Aditxt, Inc. has amended its acquisition agreement with Appili Therapeutics and filed pro forma financial statements reflecting the acquisitions of both Appili and Evofem Biosciences.

Aditxt, Inc. and Appili Therapeutics, Inc. have agreed to extend the deadline for their acquisition agreement to September 30, 2024, while Aditxt works to secure financing.

Aditxt and Evofem have amended their merger agreement, substituting cash for stock consideration and addressing Evofem's financing needs, while Evofem has acquired SOLOSEC, a treatment for bacterial vaginosis and trichomoniasis.

Aditxt, Inc. has entered into a securities purchase agreement, issuing a senior note for $625,000 and amending existing warrants to lower the exercise price to $1.49 per share.

Aditxt, Inc. and Appili Therapeutics, Inc. have amended their acquisition agreement, extending the outside date and financing deadline to August 30, 2024.

Aditxt, Inc. received a $50,000 loan from Sixth Borough Capital Fund, LP, and issued a new subordinate note for $116,806, including an original issue discount, after defaulting on a previous loan.